创胜集团-B(06628.HK):于2025年ASCO年度大会首次公布 Osemitamab(TST001)三联疗法治疗一线胃或胃食管结合部腺癌的中位生存期新数据的最新业务进展

格隆汇
02 Jun

格隆汇6月2日丨创胜集团-B(06628.HK)公布,Osemitamab (TST001)联合纳武利尤单抗和CAPOX作为晚期胃或胃食管结合部腺癌(TranStar102)一线治疗的一项正在进行的II期临床试验G队列更新研究数据。该研究结果以壁报形式(摘要编号:#4032) 亮相于再美国伊利诺伊州芝加哥市举行的2025年美国临床肿瘤学会年会(ASCO 2025)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10